Vidya Limaye1,2, Chris Bundell3, Peter Hollingsworth3,4, Arada Rojana-Udomsart3, Frank Mastaglia5, Peter Blumbergs2, Sue Lester6. 1. Rheumatology Department, Royal Adelaide Hospital, North Tce, Adelaide, South Australia SA, 5000, Australia. 2. Discipline of Medicine, Adelaide University, Adelaide, South Australia, Australia. 3. PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Perth, Western Australia, Australia. 4. Clinical Immunology, Sir Charles Gairdner Hospital. 5. West Australian Neuroscience Research Institute, Queen Elizabeth II Medical Centre, Perth, Western Australia, Australia. 6. Rheumatology Department, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Abstract
INTRODUCTION: Inhibition of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) with statins may trigger idiopathic inflammatory myositis (IIM) or immune-mediated necrotizing myopathy (IMNM). Anti-HMGCR antibodies have been detected in patients with IIM/IMNM. We aimed to determine the associations of anti-HMGCR in IIM/IMNM. METHODS: Anti-HMGCR antibodies were detected by ELISA in sera from patients with IIM/IMNM. RESULTS: Anti-HMGCR antibodies were detected in 19 of 207 patients with IIM/IMNM, and there was a trend toward an association with male gender (P = 0.079). Anti-HMGCR antibodies were associated strongly with statin exposure (OR = 39, P = 0.0001) and HLA-DRB1*11 (OR = 50, P < 0.0001). The highest risk for development of anti-HMGCR antibodies was among HLA-DR11 carriers exposed to statins. Univariate analysis showed a strong association of anti-HMGCR antibodies with diabetes mellitus (P = 0.008), which was not confirmed by multiple regression. Among anti-HMGCR(+) patients there was a trend toward increased malignancy (P = 0.15). CONCLUSIONS: Anti-HMGCR antibodies are seen in all subtypes of IIM and IMNM and are associated strongly with statin use and HLA-DR11. Muscle Nerve 52: 196-203, 2015.
INTRODUCTION: Inhibition of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) with statins may trigger idiopathic inflammatory myositis (IIM) or immune-mediated necrotizing myopathy (IMNM). Anti-HMGCR antibodies have been detected in patients with IIM/IMNM. We aimed to determine the associations of anti-HMGCR in IIM/IMNM. METHODS: Anti-HMGCR antibodies were detected by ELISA in sera from patients with IIM/IMNM. RESULTS: Anti-HMGCR antibodies were detected in 19 of 207 patients with IIM/IMNM, and there was a trend toward an association with male gender (P = 0.079). Anti-HMGCR antibodies were associated strongly with statin exposure (OR = 39, P = 0.0001) and HLA-DRB1*11 (OR = 50, P < 0.0001). The highest risk for development of anti-HMGCR antibodies was among HLA-DR11 carriers exposed to statins. Univariate analysis showed a strong association of anti-HMGCR antibodies with diabetes mellitus (P = 0.008), which was not confirmed by multiple regression. Among anti-HMGCR(+) patients there was a trend toward increased malignancy (P = 0.15). CONCLUSIONS: Anti-HMGCR antibodies are seen in all subtypes of IIM and IMNM and are associated strongly with statin use and HLA-DR11. Muscle Nerve 52: 196-203, 2015.
Authors: Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson Journal: Cardiovasc Res Date: 2018-07-01 Impact factor: 10.787
Authors: Eleni Tiniakou; Iago Pinal-Fernandez; Thomas E Lloyd; Jemima Albayda; Julie Paik; Jessie L Werner; Cassie A Parks; Livia Casciola-Rosen; Lisa Christopher-Stine; Andrew L Mammen Journal: Rheumatology (Oxford) Date: 2017-05-01 Impact factor: 7.580
Authors: O Shovman; B Gilburd; C Chayat; A Dortort Lazar; H Amital; M Blank; C Bentow; M Mahler; Y Shoenfeld Journal: Immunol Res Date: 2017-02 Impact factor: 2.829